Accustem Sciences Inc. ACUT
We take great care to ensure that the data presented and summarized in this overview for Accustem Sciences Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in ACUT
Top Purchases
Top Sells
About ACUT
AccuStem Sciences, Inc. operates as a life sciences company focusing on improving outcomes for patients with cancer. It develops StemPrintER technology, a multi-gene prognostic assay to predict the risk of recurrence of Endocrine receptor-positive /HER2- breast cancer; and Spare, a derivative of StemPrintER that combines StemPrintER with two clinical markers. The company is based in New York, New York.
Insider Transactions at ACUT
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 30
2022
|
Gabriele M Cerrone Director |
BUY
Open market or private purchase
|
Indirect |
5,000
+0.13%
|
$5,000
$1.4 P/Share
|
|
Dec 02
2022
|
Gabriele M Cerrone Director |
BUY
Open market or private purchase
|
Indirect |
3,729
+0.1%
|
$3,729
$1.42 P/Share
|
|
Nov 18
2022
|
Gabriele M Cerrone Director |
BUY
Open market or private purchase
|
Indirect |
24,500
+0.63%
|
$24,500
$1.05 P/Share
|
|
Aug 01
2022
|
Gabriele M Cerrone Director |
BUY
Open market or private purchase
|
Indirect |
10,000
+0.26%
|
$0
$0.79 P/Share
|
|
Jun 08
2022
|
Gabriele M Cerrone Director |
BUY
Open market or private purchase
|
Indirect |
20,000
+0.52%
|
$0
$0.5 P/Share
|
|
Apr 26
2022
|
Gabriele M Cerrone Director |
BUY
Open market or private purchase
|
Indirect |
5,266
+0.14%
|
$5,266
$1.49 P/Share
|
|
Apr 25
2022
|
Gabriele M Cerrone Director |
BUY
Open market or private purchase
|
Indirect |
4,181
+0.11%
|
$4,181
$1.35 P/Share
|